Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q90101336)
Watch
English
Talazoparib: First Global Approval
scientific article published on 01 December 2018
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
title
Talazoparib: First Global Approval
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
author name string
Sheridan M Hoy
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
publication date
1 December 2018
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
published in
Drugs
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
volume
78
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
issue
18
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
page(s)
1939-1946
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
cites work
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/30506138
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1007/S40265-018-1026-Z
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
PubMed publication ID
30506138
1 reference
stated in
Europe PubMed Central
PubMed publication ID
30506138
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30506138%20AND%20SRC:MED&resulttype=core&format=json
retrieved
11 April 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit